Subject is between  years old and  years old, inclusive
Must be at least  years old and enrolling on SJMB
At least  years old at time of consent to remediation intervention
>=  and <  years old at enrollment
Adult (?  years old)
Treatment-naive participants with AML who are >/= years old
Patients ?  years old
Man or woman >=  years old.
Patients must be at least  years old.
DONOR: <  months old and >  years old
Subjects  and  (in cohort ) will be >=  years old
Performance status: Lansky >=  for patients who are =<  years old and Karnofsky >= % for patients who are >  years old
Men or women ?  years old at the time of signing the ICF
Patients  to  years old
Age ? years old
The patient is ? years old.
The patient is at least  years old.
Subjects less than  years old are being excluded in this study as melanoma is extremely uncommon in this age group and insufficient data are available in adults using dendritic cell therapy to assess potential risk in subjects less than  years old. Participation of women and minorities is encouraged, although it is recognized that melanoma is much more common in the Caucasian population
Patients - years old will be enrolled in Arm A or C (high-intensity)
Patient must be at least  years old at the time of consent.
Patients must be at least  years old.
Is aged ? years old in Japan or ? years old in other countries
Age ? years old
Karnofsky >= % for patients >  years old, and Lansky >=  for patients - years old
Initially only patients who are >=  years old will receive HA- TCR T cell infusions on the protocol; younger patients may be screened, enrolled in the protocol and monitored for relapse but will not be eligible for infusion until at least one patient >=  years old has been treated and discussed with the Food and Drug Administration (FDA)
At least  years old at the time of informed consent
Age greater than or equal to  years old; if patients - years old are enrolled in the trial, they will only be enrolled after  patients >=  years old have been treated, and the treatment has been shown to be safe
Patients ? years and ? years old (The  first patients at Dose Level  will be <  years old. Enrollment of patients ?  years old must be approved by the DSMB after the completion of cohort ).
Patient is ?  years old at the time of informed consent.
Patients enrolled onto the dose-finding phase of the study must have an identified donor and transplant strategy prior to initiation of the lymphodepletion regimen. Patients enrolled in the Expansion Phase of the Study: Relapsed/Refractory Cohort  Patients ? years old with relapsed or primary refractory acute myeloid leukemia. Patients Enrolled in the Dose-Escalation Phase of the Study Patients ? years and ? years old (The  first patients at Dose Level  will be < years old. Enrollment of patients ?  years old must be approved by the DSMB after the completion of cohort ) Newly Diagnosed Cohort  Patients with newly diagnosed, untreated Acute Myeloid Leukemia (as defined by World Health Organization (WHO) criteria,) who meet criteria for the European Leukemia Net (ELN) Adverse genetics prognostic group. Eligibility criteria for UCART administration
The first  patients must be >=  and =<  years old. The subsequent patients may include pediatric patients >=  and =<  years old. Eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician.
Creatinine =< . mg/dL for patients  years old and older and =<  for patients younger than  years old.
Eastern Cooperative Oncology group (ECOG) =<  for patients >=  years old or Lansky play >= % for patients\r\n=<  years old
CELL PROCUREMENT: Karnofsky score > % if >=  years old or Lansky performance score of greater than % if <  years old
LYMPHODEPLETION: Karnofsky score > % if >=  years old or Lansky performance score of greater than % if <  years old
Female ?  years old.
IMMUNE RECONSTITUTION STUDY ONLY: Between  and  years old
DONOR: Must be >=  years old
Age ?  years old (?  years old in Japan);
>  years old
Patients must be ?  years old.
Performance status < % in patients  years old or greater, < % in patients less than age  years
At least  years old;
Performance status:\r\n* Lansky >=  for individuals  months- =<  years old; Karnofsky > % for individuals - years old
Man or woman >=  years old.
Patients age  to  years old; eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age - years may be enrolled after at least  adults (ages - years old) have been assessed for safety at day 
Age <-years-old.
Eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age - years old may be enrolled after at least  adults (ages - years old) have been treated without toxicity
DONOR: Less than  years old
Lansky performance status of >= % for participants  years old or younger
Age ?  years old.
Male or female patients from  months to ?  years old at the time of study enrollment
Age: ? months to < years old at the time of informed consent
Age ?  years old
Patients  to =<  years: Karnofsky (>=  years old) >=  or Eastern Cooperative Oncology Group (ECOG) -
Age ?  years old.
Patients ? year old
Patients must be >  years old.
Donor: Donor <  months old, >  years old
The patient is ?  years old.
The patient is ?  years old.
Age ?  years old
Lansky score >% for participants < years old.
pediatric Phase  Part B:  to < years old
Participants who are  to  years old would be enrolled after consultation with the Medical Monitor
Are a male or female patient ? years old.
DONOR: Children <  years old
Adult Women (?  years old).
Age ?  years old
Be  years old at the time the informed consent is signed
? years old.
Performance status: Lansky >=  for patients who are =<  years old and Karnofsky >= % for patients who are >  years old
Patient must be ?  years old.
Patients must be at least  years old.
Men and women ? years old.
Are a male or female participants ? years old.
Age <-years-old.
Patients ?  years old
Patient must be at least  years old.
Performance status: Karnofsky or Lansky scores ?  for subjects >  years old or ?  years old, respectively.
Age <-years-old.
Male or female patients ? years old.
Age < -years-old.
Patients  years old or greater
Lansky (<  years old) >= 
Patients > or =  years old
?  years old at the time of informed consent.
Performance status: Lansky >=  for individuals  months to <  years old; Karnofsky > % for individuals - years old
Patients must be >/=  years old.
? years old
At Childrens National Medical Center only: age >  years old and < 
At University of Oklahoma: age >  years old and =<  years for recipient
Age >= years old
? years old
Lansky >=  for patients =<  years old; Karnofsky >=  for patients >  years old
Male or female ? years old
Donor >=  years old
Male or female patient is ?  years old,
Male and female TAM patients ?  years old at the time of first dose administration. Patients <  years old can only be included in the study after first IA has shown that it is safe and well tolerated in patients ?  years old (Section .).
Age ?  years old.
Male or female patients ?  years old
Age <-years-old.
Age ?  years old.
Age <  years old and >  months
Adults >/=  years old
Age - years old at the time of consent
Is > years old;
Male or female ? years old.
Patient is an adult, female ?  years old at the time of informed consent
Performance status: Lansky >=  for patients who are =<  years old and Karnofsky >= % for patients who are >  years old
?  years old
Men or women >  years old
? years old, diagnosed with persistent or chronic ITP
Man or woman >=  years old.
Subjects >= years old.
Adults >/=  years old
?  years old Part , dose expansion:
Is the subject between  years old and  years old inclusive?
The subject is at least  years old.
Patient is an adult ?  years old at the time of informed consent.
Age >/= years old.
- years old
Men or women >  years old
The patient is ? years old.
? years old
In patients >  years old, documented LVEF of less than or equal to %
Patients must be greater than or equal to  years old.
Men or women ? years old
Male or female patients ? years old.
Men or women ?  years old
For patients <  years old: at least two induction chemotherapy treatments.
Patients above >=  years old should have an age-adjusted co-morbidity index of =< 
Adults ?  years old
Male or female patients >=  years old
Patients treated at collaborating sites and current St. Jude patients who are on therapy or within  years of completion of therapy must be =<  years old; all other St. Jude patients must be =<  years old
Performance status: Lansky >=  for patients who are =<  years old and Karnofsky >= % for patients who are >  years old
Subject is female and is at least  years old
<  years old
<  years old
Age  years old to  years old
Are at least  years old
Are - years old
Patients who are in close social contact with children under  years old
Adult (? years old)
- years old
Male  to  years old
Female  to  years old
- years old,
The patient is ? years old,
Patients age ? years old
> years old.
FLT PET: will only be performed in patients >=  years old
Patient is <  years old at the time of the drug administration
? years old
M/F at least  years old
Male patients age ? years old
Male, age between - years old
Be age ?  years old.
History of treatment for cancer or related illness diagnosed at =<  years old
The patient is at least  years old.
Women ?  years old
